Is α7-nAChR a possible target for lung cancer and malignant pleural mesothelioma treatment?

Current Drug Targets

Volumn 13, Issue 5, 2012, Pages 688-694

  Cesario, Alfredo ^a,b   Russo, Patrizia ^a   Nastrucci, Candida ^a   Granone, Pierluigi ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antineoplastic effect; Apoptosis; D tubocurarine; MPM; NSCLC; cobratoxin

Indexed keywords

BUNGAROTOXIN RECEPTOR; CISPLATIN; COBROTOXIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PLEURA MESOTHELIOMA;

EID: 84860486206     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800398900     Document Type: Article

References (46)

1. Swindle EJ, Collins JE, Davies DE. Breakdown in epithelial barrier function in patients with asthma: identification of novel therapeutic approaches. J Allergy Clin Immunol 2009; 124: 23-34.
2. Jantz MA, Antony VB. Pathophysiology of the pleura. Respiration 2008; 75: 121-133.
3. International Agency for Research on Cancer. Tobacco smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, IARC, vol. 83.
4. Raviv S, Hawkins KA, Decamp Jr MM, Kalhan R. Lung Cancer in Chronic Obstructive Pulmonary Disease: Enhancing Surgical Options and Outcomes. Am J Respir Crit Care Med 2011; 183: 1138-1146.
5. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immuno editing and immuno sculpting pathways to cancer progression. Semin Cancer Biol 2007; 17: 275-287.
6. Russo P, Cesario A, Rutella S, et al. Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment. Curr Med Chem 2011; 18: 91-112.
7. Kummer W, Lips KS, Pfeil U. The epithelial cholinergic system of the airways. Histochem Cell Biol 2008; 130: 219-234.
8. Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 2007; 115: 208-222.
9. Paleari L, Grozio A, Cesario A, Russo P. The cholinergic system and cancer. Semin Cancer Biol 2008; 18: 211-217.
10. Grozio A, Catassi A, Cavalieri Z, et al. Nicotine, lung and cancer. Anticancer Agents Med Chem 2007; 7: 461-466.
11. Russo P, Catassi A, Cesario A, Servent D. Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr Med Chem 2006; 13: 3493-3512.
12. Trombino S, Bisio A, Catassi A, Cesario A, Falugi C, Russo P. Role of the non-neuronal human cholinergic system in lung cancer and mesothelioma: possibility of new therapeutic strategies. Curr Med Chem Anticancer Agents 2004; 4: 535-542.
13. Wessler I, Kirkpatrick CJ, Racké K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 1999; 26: 198-205.
14. Song P, Spindel ER. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 2008; 106: 180-185.
15. Sekhon HS, Song P, Jia Y, Lindstrom J, Spindel ER. Expression of lynx1 in developing lung and its modulation by prenatal nicotine exposure. Cell Tissue Res 2005; 320: 287-297.
16. Miwa JM, Ibanez-Tallon I, Crabtree GW, et al. Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 1999; 23:105-114.
17. Maouche K, Polette M, Jolly T, et al. {alpha}7 nicotinic acetylcholine receptor regulates airway epithelium differentiation by controlling basal cell proliferation. Am J Pathol 2009; 175: 1868-1882.
18. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009; 9: 195-205.
19. Schuller HM. Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 2007; 39: 45-63.
20. Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008; 29: 151-158.
21. Thunnissen FB. Acetylcholine receptor pathway and lung cancer. J Thorac Oncol 2009; 4: 943-946.
22. Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res 2008; 659: 221-231.
23. Cesario A, Russo P, Viaggi S, et al. Malignant pleural mesothelioma: time for translational research. Lancet Oncol 2004; 5: 591-592.
24. Minna JD. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest 2003; 111: 31-33.
25. Waser PG. Chemistry and pharmacology of natural curare compounds. In: Neuromuscular Blocking and Stimulating Agents. Int. Enc. Pharmacol. Ther. Cheymol, J. Ed. 1972; Section 14, Vol. 1, 205-239. Oxford: Pergamon Press.
26. Grozio A, Paleari L, Catassi A, et al. Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int J Cancer 2008; 122: 1911-1915.
27. Trombino S, Cesario A, Margaritora S, et al. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004; 64: 135-145.
28. Strippoli R, Benedicto I, Perz Lozano ML, et al. Epithelial-tomesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-κB/Snail-1 pathway. Dis Model Mech 2008; 1: 264-274.
29. Julien S, Puig I, Caretti E, et al. Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchymal transition. Oncogene 2007; 26: 7445-7446.
30. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569-581.
31. Antil-Delbeke S, Gaillard C, Tamiya T, et al. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal a7-nicotinic acetylcholine receptor. J Biol Chem 2000; 275: 29594-29601.
32. Carlisle DL, Liu X, Hopkins TM, et al. Nicotine activates cellsignaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2007; 20(6): 629-641.
33. Lam DC, Girard L, Ramirez R, et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007; 67: 4638-4647.
34. Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2007; 86-91.
35. Chen J, Emara N, Solomides C, Parekh H, Simpkins H. Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol 2010; 66: 1103-1111.
36. Doillon CJ, Gagnon E, Paradis R, Koutsilieris M. Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity. Anticancer Res 2004; 24: 2169-2177.
37. Antil S, Servent D, Ménez A. Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of alphacobratoxin. J Biol Chem 1999; 274: 34851-34858.
38. Sher E, Giovannini F, Boot J, Lang B. Peptide neurotoxins, small-cell lung carcinoma and neurological paraneoplastic syndromes. Biochimie 2000; 82: 927-936.
39. Fruchart-Gaillard C, Gilquin B, Antil-Delbeke S, et al. Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor. Proc Natl Acad Sci USA 2002; 99: 3216-3221.
40. Antil-Delbeke S, Gaillard C, Tamiya T, et al. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor. J Biol Chem 2000; 275: 29594-29601.
41. Russo P, Paleari L, Catassi A, et al. Neuronal Cholinergic Toxines: possible drugs for lung cancer treatment. In: Goudey-Perriere, Ed. Toxines et fonctions cholinergiques neuronales et non neuronales. Lavoisier 2008; pp. 63-67.
42. Catassi A, Paleari L, Servent D, et al. Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer 2008; 44: 2296-2311.
43. Keller SH, Kreienkamp HJ, Kawanishi C, Taylor P. Molecular determinants conferring a-toxin resistance in recombinant DNAderived acetylcholine receptors. J Biol Chem 1995; 270: 4165-4171.
44. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides, Nature Rev 2003; 2: 790-802.
45. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002; 110: 527-536.
46. Paleari L, Catassi A, Ciarlo M, et al. Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 2008; 41: 936-959.